Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, diabetes experts warn.

Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year ...

Let’s face it—managing diabetes can feel like you’re walking through a nutritional minefield. One wrong step and your blood sugar goes haywire, leaving you feeling like garbage for hours.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes. The research, published April 1 in the ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...